Board of Directors

Steven R. Peabody

Executive Chairman & Chief Innovation Officer

Peabody is the Chief Executive Officer and the Chairman of the Board of VoCare, Inc. Peabody is known for his entrepreneurial stewardship in product development and remarkable business savvy in the success of CMI – the engineering firm he acquired in 1992. Through the continuing use of new technology to streamline processes and develop new products, Peabody not only ensured that each business opportunity succeeded as a spin-off company, but also as one of the best in its respective field.

CMI has developed several hundred products for various Fortune 500 companies totaling over $250 million in revenue. Peabody has been singularly responsible for this achievement. He has also been personally involved in the product audits and certifications in the fields of: FCC; FDA; ICC; UL; ASTM; AGA; CGA; ICC; ISO9001; and TS9000.

Peabody used his vision combined with his management skill to build executive teams to turn product ideas from startups to dynamic growth companies. During his 17 years of leadership at CMI, Peabody exploited the full potential of international resources to substantially increase the capabilities of CMI as a product development company. Peabody designed, engineered, manufactured and marketed several proprietary products to a variety of industries and has received numerous awards. Peabody currently holds 17 U.S. patents under his name for a variety of products and exclusive designs. Peabody streamlined the company, by holding all the intellectual property and outsourcing manufacturing and other services, to transition easily into niche markets with new product ideas and keeping development at greatly reduced costs. He has established and still maintains numerous business relationships with a variety of high tech domestic and international manufacturers. Peabody is considered an authority on product development and has substantial expertise with supply chain management, including offshore manufacturing

James Anderson

Jr., M.D., FFPM, FACE

Dr. Anderson is a diabetologist and endocrinologist who has been in military medicine and the pharmaceutical industry for more than 40 years. A graduate of Centenary College of Louisiana, he earned his M.D. degree from LSU School of Medicine in New Orleans, followed by Internship and Internal Medicine Residency at Charity Hospital in New Orleans. Dr. Anderson began his Fellowship in Endocrinology and Metabolism at LSU and completed it at the Medical College of Virginia in Richmond.

Following his training, he served as Chief of Medicine at the US Army Medical Research Institute for Infectious Diseases, Ft. Detrick, Maryland where he continued his studies of the effect of infection on diabetes as well as worked on biological warfare defense, vaccines, and safe care of patients with high hazard infectious diseases. He also served as the safety physician for the very first Level 3 recombinant DNA experiments performed by the US NIH. Lt. Col. Anderson then moved to Brooke Army Medical Center at Ft Sam Houston, San Antonio, Texas where he served as Chairman of the Department of Clinical Investigation and Consultant to the Surgeon General of the Army for Clinical Investigation. During that time he acquired the Army’s first artificial pancreas to aid in the investigation of immune factors in the etiology of diabetes. While in San Antonio, he also was an independent investigator for Lilly’s development of rDNA human insulin for therapeutic use.

Dr. Anderson then joined Eli Lilly and Company where he was responsible for Lilly’s global clinical diabetes/endocrine development program. He managed diabetes and cardiometabolic drug development, and drove the clinical development, registration and launch of two families of billion dollar diabetes care products, Humulin® (human insulin of rDNA origin) and Humalog®, the first rapid-acting analog of human insulin for which he is one of the inventors. He led the clinical development and was responsible for 6 US NDAs, and had clinical responsibility for all insulin products worldwide.   He also evaluated and conducted the initial clinical development of human insulin and insulin analog pre-mixtures, basal insulin analogs, pulmonary and oral insulin as well as a small molecule, oral drugs for type 2 diabetes. Dr. Anderson re-focused the strategic clinical direction for marketed products and investigational drugs, the conduct of global clinical trials and the clinical development of numerous compounds in Phase I- Phase IV. He held pivotal roles directing Lilly’s endocrine products in Japan, global medical-marketing, internal discovery, and in-licensing opportunities. He was the first in the industry to envision and accomplish a strategic concurrent global clinical development and registration program, which secured a first to market position for Lilly’s Humalog. Prior to retiring from Lilly, Dr. Anderson led the initial development of Lilly’s newest drug for diabetes – dulaglutide [Trulicity™] (which is Lilly’s third billion-dollar diabetes drug).

A strong believer in education, Dr. Anderson has served on the medical faculties of LSU School of Medicine, Medical College of Virginia, Uniformed Services University of the Health Sciences, the University of Texas Health Science Center San Antonio, and Indiana University School of Medicine where he is currently a Clinical Associate Professor of Medicine for the Division of Endocrinology and Metabolism.

Internationally recognized, Dr. Anderson is an elected Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK and was a founding board member of the American Association of Pharmaceutical Physicians. He is also a Fellow of the American College of Endocrinology. He is a founding editorial board member of two journals for diabetes, and serves on the editorial boards or is a reviewer for 5 other diabetes/endocrine journals. He has also served in local, regional and national positions with the American Diabetes Association.

In addition to serving as Medical Director for PTS Diagnostics in Indianapolis, he currently holds positions as President and CEO of MitoZyme Inc (Carmel, IN and Boston), CEO of Diabetes and CardioMetabolic Disease Solutions Group (Carmel) and Medical Director of Know Labs (Seattle). Dr. Anderson has served as Senior Scientific Advisor and is currently a member of the Board of Directors for Generex Biotechnology Corporation (Miramar, Florida and Burlington, Ontario).

Jim Parker

A seasoned executive with over 30 years of strategic, executive-level experience across the healthcare industry.

Until January 2021, Jim served as Health and Human Services Secretary Alex Azar’s Senior Advisor for Health Reform.  In this role, Jim oversaw the achievement of several initiatives that will improve the US healthcare markets, including policies that promote the use of telehealth and remote patient monitoring.

Before his government service, Jim held senior executive payer and provider leadership roles, most notably with Anthem and Indiana University Health.

Jim obtained his undergraduate degree from Kenyon College and an MBA from The Ohio State University.  He resides with his family in Indianapolis, IN.

James (Zhibo) Lu

Global Source One (GSO)

Lu brings many years of experience in product/process development and quality management to VoCare’s Board of Directors. Lu established Global Source One (GSO), a multinational company that provides supply chain management for companies that need high quality products and competitive production solutions. Lu has also developed a number of qualified suppliers and affiliated factories in China to produce parts for many customers in the North American market, with products ranging from appliances, automotive, drilling, to general industries such as packaging and printing. Before he founded his company in 2004, Lu worked at Cummins for 8 years, where he led a quality program for electronic components and engine parts designed to work with many suppliers for product and manufacturing process development and improvement.

Samuel Odle

Samuel Odle is a senior policy advisor for Bose Public Affairs Group. In this capacity, Sam works with clients on a variety of public policy issues involving healthcare, life sciences, technology, and education. He also assists women-owned and minority-owned businesses (MBE/WBEs) with partnership development, procurement, and strategic business advisory services. Sam also serves as president of VeriVitae LLC and a director with Alder Bowman Executive Consultation and Search. Alder Bowman recruits’ candidates to fill vital leadership roles in healthcare and life sciences. Prior to joining Bose Public Affairs Group, Sam served as the chief operating officer of Indianapolis-based IU Health and held the position of CEO of both Methodist Hospital and University Hospital. He retired in July 2012 after a career that started as vice president of operations at Methodist Hospital in 1981.

Sam has been recognized on several occasions for both his professional and community service. In 2011, Sam received the Greater Indianapolis Progress Committee “Charles L. Whistler Award” for his visionary and enthusiastic leadership in serving the community in addition to his success in bringing together the public and private sectors for civic improvement in Indianapolis. In 2007, Sam was inducted into the Indiana Business Hall of Fame. He holds honorary doctorate degrees from Martin University and Marian University.

Gary Padjen

Padjen is a former NFL linebacker for the Baltimore and Indianapolis Colts.  After his retirement from professional football, Padjen became an entrepreneur with a string of successful business ventures. An early investor in VoCare, and successful corporate fundraiser, Gary has a large network of business and personal contacts and currently owns and operates an impressive portfolio of business interests.  Padjen is a Principal with the Emerald Neuro Recover Functional Medical Clinic and is also actively involved with a Security Technology Company that provides personal protection and asset tracking products.  Padjen’s interests also include renewable, solar, wind, and oil and gas exploration projects within the energy sector. Padjen is also involved in a number of philanthropic programs and previously served on the board and as Vice President of the NFL Alumni Association-Indianapolis Chapter.